Galderma Group (GALD) Stock Overview
Operates as a dermatology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GALD from our risk checks.
GALD Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Galderma Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 159.80 |
| 52 Week High | CHF 170.10 |
| 52 Week Low | CHF 73.10 |
| Beta | -0.11 |
| 1 Month Change | 5.83% |
| 3 Month Change | -3.27% |
| 1 Year Change | 109.99% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 149.69% |
Recent News & Updates
Recent updates
Is Galderma Group AG (VTX:GALD) Trading At A 40% Discount?
Oct 29
Is Galderma Group (VTX:GALD) A Risky Investment?
Aug 24Investors Appear Satisfied With Galderma Group AG's (VTX:GALD) Prospects As Shares Rocket 28%
May 20
Nemluvio Launch And Global Expansion Will Shape Therapeutic Dermatology Markets
Launch of Nemluvio and international expansion in China and India are expected to significantly boost revenue growth and market share.Shareholder Returns
| GALD | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 2.1% | -0.5% | 1.8% |
| 1Y | 110.0% | 41.4% | 17.5% |
Return vs Industry: GALD exceeded the Swiss Pharmaceuticals industry which returned 42.7% over the past year.
Return vs Market: GALD exceeded the Swiss Market which returned 17.1% over the past year.
Price Volatility
| GALD volatility | |
|---|---|
| GALD Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 8.2% |
| 10% least volatile stocks in CH Market | 2.3% |
Stable Share Price: GALD has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: GALD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 7,676 | Flemming Ornskov | www.galderma.com |
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology.
Galderma Group AG Fundamentals Summary
| GALD fundamental statistics | |
|---|---|
| Market cap | CHF 37.48b |
| Earnings (TTM) | CHF 483.72m |
| Revenue (TTM) | CHF 4.14b |
Is GALD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GALD income statement (TTM) | |
|---|---|
| Revenue | US$5.24b |
| Cost of Revenue | US$1.63b |
| Gross Profit | US$3.61b |
| Other Expenses | US$3.00b |
| Earnings | US$613.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 23, 2026
| Earnings per share (EPS) | 2.61 |
| Gross Margin | 68.86% |
| Net Profit Margin | 11.70% |
| Debt/Equity Ratio | 32.0% |
How did GALD perform over the long term?
See historical performance and comparisonDividends
Does GALD pay a reliable dividends?
See GALD dividend history and benchmarks| Galderma Group dividend dates | |
|---|---|
| Ex Dividend Date | Apr 24 2026 |
| Dividend Pay Date | Apr 28 2026 |
| Days until Ex dividend | 13 days |
| Days until Dividend pay date | 17 days |
Does GALD pay a reliable dividends?
See GALD dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 06:19 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galderma Group AG is covered by 30 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Gordon | Barclays |
| Yihan Li | Barclays |
| Bethan Davies | Berenberg |